Stockscreener 앱 받기
52.91
1.75%
0.91
Tarsus Pharmaceuticals Inc 주식(TARS)의 최신 뉴스
Tarsus Pharmaceuticals (NASDAQ:TARS) Hits New 52-Week HighHere's What Happened - MarketBeat
When the Price of (TARS) Talks, People Listen - Stock Traders Daily
Tarsus Pharmaceuticals: Worthy Of A Small Bet (NASDAQ:TARS)🤭 Experimente a diversão no C333Bet - Oficjalny Portal Gminy Brzesko
Wellington Management Group LLP Acquires 18,019 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Tarsus Pharmaceuticals: Worthy Of A Small Bet (NASDAQ:TARS❌ Ilumine seu dia com Estrela BRT - Oficjalny Portal Gminy Brzesko
Tarsus Pharmaceuticals Insider Lowered Holding By 16% During Last Year - Simply Wall St
Lord Abbett & CO. LLC Acquires 131,636 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks - Seeking Alpha
Tarsus Pharmaceuticals' SWOT analysis: eye care stock's growth trajectory By Investing.com - Investing.com Australia
Tarsus Pharmaceuticals' SWOT analysis: eye care stock's growth trajectory - Investing.com
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap DownTime to Sell? - MarketBeat
The Manufacturers Life Insurance Company Has $1.08 Million Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals Stock Hits 52-Week High at $53.02 By Investing.com - Investing.com South Africa
Tarsus Pharmaceuticals Stock Hits 52-Week High at $53.02 - Investing.com
Tarsus Pharmaceuticals: Early Rollout Exceeding Expectations (NASDAQ:TARS) - Seeking Alpha
Charles Schwab Investment Management Inc. Buys 28,130 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
23,199 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Purchased by Verition Fund Management LLC - MarketBeat
Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet - MSN
Tarsus stock Buy rating intact as Guggenheim tracks Xdemvy's Demodex blepharitis launch - Investing.com UK
Vestal Point Capital LP Invests $7.57 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Healthcare of Ontario Pension Plan Trust Fund Trims Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Analysts Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) PT at $54.20 - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Ally Bridge Group NY LLC Makes New $10.59 Million Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Reduces Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Midday Stock Roundup: Chipotle stock up as chain announces 2% hike in menu prices - Orange County Business Journal
Tarsus Pharmaceuticals' SWOT analysis: XDEMVY success drives stock outlook - Investing.com
Mutual of America Capital Management LLC Invests $4.29 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Jennison Associates LLC Buys 698,712 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - MSN
Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade - MSN
The Goldman Sachs Group Boosts Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $41.00 - Defense World
22,493 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Purchased by GSA Capital Partners LLP - MarketBeat
What is Lifesci Capital's Forecast for TARS FY2024 Earnings? - MarketBeat
Tarsus Pharmaceuticals Appoints Kate Goodrich, MD, to its Board of Directors - Vision Monday
US$65.33That's What Analysts Think Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Worth After These Results - Simply Wall St
Tarsus Pharmaceuticals stock target upgraded, holds buy on strong sales - Investing.com
Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Down 5.3%Here's What Happened - MarketBeat
Trend Tracker for (TARS) - Stock Traders Daily
Tarsus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
The Goldman Sachs Group Forecasts Strong Price Appreciation for Tarsus Pharmaceuticals (NASDAQ:TARS) Stock - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2024 Earnings Call Transcript - Insider Monkey
Tarsus Pharmaceuticals stock target upgraded, holds buy on strong sales By Investing.com - Investing.com UK
Paradigm Biocapital Advisors LP Increases Stake in Tarsus Pharma - GuruFocus.com
Prudential Financial Inc's Strategic Acquisition in Tarsus Pharm - GuruFocus.com
Tarsus Pharmaceuticals (NASDAQ:TARS) Hits New 1-Year High After Analyst Upgrade - Defense World
Tarsus Pharmaceuticals stock soars to 52-week high of $52 - Investing.com
Tarsus Pharmaceuticals (NASDAQ:TARS) Reaches New 52-Week High After Analyst Upgrade - MarketBeat
Tarsus Pharmaceuticals stock soars to 52-week high of $52 By Investing.com - Investing.com UK
Tarsus Pharmaceuticals (NASDAQ:TARS) Given New $65.00 Price Target at Oppenheimer - MarketBeat
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ... - Yahoo Finance
Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ... By GuruFocus - Investing.com Canada
Tarsus Pharmaceuticals Reports Strong Q3 2024 Performance - TipRanks
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings: EPS of $(0.6 - GuruFocus.com
2.88%
2.65%
자본화:
|
볼륨(24시간):